Tilray (TLRY) seems to be weak long term investment but strong short term
Tilray Inc (TLRY) currently trades at $6.13 and has grown by 10.65% today. Tilray is a pharmaceutical company focused on the development of cannabis-based medicines, drugs, drops, and oil products. The company is headquartered in Canada but serves clients worldwide. The pot company can be a bad, high-risk 1-year investment option.
Based on this information, investorsQ rates this stock 4 out of 10. We give it this rating based on current information written in this article. The high forecast for Tilray Inc is $28.00 and the low is $2.00. Notably, the company’s market cap is $675.59 million with a 52 week high of $61.56 and a 52 week low of $2.43. TLRY has gained up to $0.59 from the previous closing price of $5.54. TLRY has changed in price by -50.53 per share in the last 12 months.